Solta Medical, a provider of fractional resurfacing and non-invasive skin tightening and a provider in aesthetic skin treatments, has received FDA 510(k) clearance of its Fraxel re:store Dual laser system for the treatment of actinic keratosis (AKs).
The Fraxel system takes the fractional laser technology to the next level by adding a 1927nm wavelength, the first ever application of a Thulium laser in the aesthetics market.
Solta Medical claims that the Fraxel re:store Dual treatment provides superior results for the removal of Aks.
Solta Medical board chairman, president and CEO Stephen Fanning said that Solta Medical continues to develop safe, anti-aging solutions that deliver the best possible results in non-invasive aesthetic treatments.
“With the FDA clearance of our Fraxel re:store Dual system, we are providing our physicians with technology that patients are seeking, specifically in terms of reversing sun damage and treating precancerous skin lesions,” Fanning said.